Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

TNS Energo Yaroslavl reported for 3 months of 2024 by RAS

5/2/24 YRSB

Board of Directors of SFI recommended that dividends be paid for 2023

5/2/24 SFIN

Seligdar reports for 3 months of 2024 by RAS

5/2/24 SELG

Globaltrans shareholders have decided not to pay dividends

4/30/24 GLTR

ZIL reported for 2023 by IFRS

4/29/24 ZILL

Rosseti reported for 3 months of 2024 by RAS

4/29/24 FEES

Mechel reported for 3 months of 2024 by RAS

4/29/24 MTLR

Novoship reports for 3 months of 2024 by RAS

4/29/24 NOMP

TZA reported for 2023 by IFRS

4/29/24 TUZA

TZA reported for 3 months of 2024 by RAS

4/29/24 TUZA